A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas: Presentation and implications of the Low PASI score

Abstract Background: The Psoriasis Area and Severity Index (PASI) is not able to measure small affected areas in a body region which is important for assessing the performance of high-effective treatment. Objective: To present the Low PASI score, show the difference between the classic PASI and the Low PASI, evaluate the inter-observer agreement of both scores, and compare the two scores within investigators. Methods: Cross-sectional study. Two investigators independently assessed the classic PASI and the Low PASI in 10 patients with mild-to-moderate plaque psoriasis. Differences in outcome between the two scores were calculated. Intra-class correlation coefficients (ICC) were used to determine the inter-observer agreement and to compare measurements of the two scores within both investigators. Prediction limits of 95% for the errors in measurements were provided. Results: In both investigators, Low PASI was mean 1.71 and 1.76, whereas the classic PASI was mean 4.14 and 4.33. The inter-observer agreement (ICC) was excellent for both investigators in both scores (ICC classic PASI = 0.95 and Low PASI = 0.87). Conclusion: The Low PASI score allows more possible scores at lower levels of psoriasis extent (affected areas lower than 10% in a body region) compared to the classic PASI. This new score may lead to a more precise analysis of treatment responses and may have important clinical implications.

[1]  C. Griffiths,et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.

[2]  J. Walsh,et al.  Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. , 2013, Journal of the American Academy of Dermatology.

[3]  A. Kimball,et al.  Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[5]  A. Finlay Current severe psoriasis and the Rule of Tens , 2005, The British journal of dermatology.

[6]  Denise Polit-O'Hara,et al.  Nursing Research: Principles and Methods , 1978 .

[7]  S. Feldman,et al.  Psoriasis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[8]  A. Stanimirović,et al.  Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead‐Sea , 2000, International journal of dermatology.

[9]  C C Jacobson,et al.  Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased , 2004, The British journal of dermatology.

[10]  F. Aubin,et al.  What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  K. Schmitt-Rau,et al.  A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis , 2008, International journal of dermatology.

[12]  Jan D Bos,et al.  How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. , 2010, The Journal of investigative dermatology.